M&T Bank Corp Boosts Holdings in United Therapeutics Corporation $UTHR

Key Points

• M&T Bank Corp increased its stake in United Therapeutics by 3,814.4% in Q4 to 45,290 shares worth about $22.07 million (roughly 0.11% of the company), while institutional investors own approximately 94.08% of the stock.
• United Therapeutics beat EPS for the quarter ($7.70 vs. $6.78) but missed revenue expectations, and analysts have raised price targets with a consensus "Moderate Buy" and a $601.50 target.
• There has been notable insider selling

M&T Bank Corp increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 3,814.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 45,290 shares of the biotechnology company's stock after buying an additional 44,133 shares during the period. M&T Bank Corp owned about 0.11% of United Therapeutics worth $22,068,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Clearstead Advisors LLC grew its stake in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after acquiring an additional 23 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock valued at $472,000 after acquiring an additional 28 shares in the last quarter. Archer Investment Corp raised its stake in shares of United Therapeutics by 9.5% in the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company's stock valued at $149,000 after acquiring an additional 31 shares in the last quarter. Signaturefd LLC boosted its holdings in United Therapeutics by 4.1% in the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company's stock valued at $437,000 after purchasing an additional 35 shares during the period. Finally, WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $470.95, for a total transaction of $10,596,375.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 10,000 shares of the company's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 430,295 shares of company stock valued at $229,488,901 over the last ninety days. 10.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on UTHR. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. TD Cowen boosted their price objective on United Therapeutics from $575.00 to $660.00 and gave the stock a "buy" rating in a research report on Monday, March 30th. Wells Fargo & Company upped their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 31st. Morgan Stanley raised their target price on shares of United Therapeutics from $471.00 to $519.00 and gave the company an "equal weight" rating in a report on Friday, April 10th. Finally, HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $601.50.

United Therapeutics Price Performance

United Therapeutics stock opened at $572.85 on Friday. The stock has a market cap of $25.11 billion, a PE ratio of 20.53, a P/E/G ratio of 1.63 and a beta of 0.75. The stock's fifty day moving average is $534.64 and its two-hundred day moving average is $493.24. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analysts' expectations of $814.80 million. During the same period in the prior year, the firm posted $6.19 EPS. The business's quarterly revenue was up 7.4% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.